• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥地利重症肌无力的流行病学:老龄化社会中患病率的上升。

Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society.

机构信息

Department of Clinical Neurology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

出版信息

Wien Klin Wochenschr. 2012 Nov;124(21-22):763-8. doi: 10.1007/s00508-012-0258-2. Epub 2012 Nov 6.

DOI:10.1007/s00508-012-0258-2
PMID:23129486
Abstract

OBJECTIVE

The purpose of this study was to investigate recent epidemiological trends of myasthenia gravis (MG) in Austria.

METHODS

We used the national hospital discharge register, which records the discharge diagnoses of all inpatient stays in Austria to calculate the yearly inpatient prevalence of MG from 1992 to 2009 (main or secondary diagnosis of MG). The population prevalence was indirectly estimated. The temporal and geographical variability of the inpatient prevalence was correlated with the number of practicing neurologists.

RESULTS

The inpatient prevalence of 2009 was calculated as 8.0 and the population prevalence as 15.69 (95 % CI 13.16-19.42) per 100,000. We observed a 2.2 fold increase in the inpatient prevalence between 1992 and 2009, which was mainly due to a rise in the number of older patients (³ 50 years). Partly this could be accounted for by an ageing of the population as a whole and a rise in the age of hospitalised patients. However, after adjusting for demographic factors an unexplained average yearly rise of 3.7-3.9 % remained. We found a significant spatial and temporal correlation of MG inpatient prevalence rates with the number of practicing neurologists, which increased over the same period.

CONCLUSIONS

The results from this study support the notion that the prevalence rate of MG in Austria is rising and near the higher end of the wide range discussed in the literature. Our data argue for the importance of specialist neurological care for the diagnosis of this disease.

摘要

目的

本研究旨在调查奥地利重症肌无力(MG)的近期流行病学趋势。

方法

我们使用国家住院登记处,该登记处记录了奥地利所有住院患者的出院诊断,以计算 1992 年至 2009 年(MG 的主要或次要诊断)MG 的年住院患病率。人群患病率是间接估计的。住院患病率的时间和空间变化与执业神经科医生的数量相关。

结果

2009 年的住院患病率计算为 8.0,人群患病率为 15.69(95%CI 13.16-19.42)/100000。我们观察到 1992 年至 2009 年间住院患病率增加了 2.2 倍,这主要是由于老年患者(³50 岁)人数增加所致。部分原因可能是整个人口老龄化和住院患者年龄增加所致。然而,在调整人口统计学因素后,仍存在每年平均 3.7-3.9%的不明原因上升。我们发现 MG 住院患病率与执业神经科医生数量之间存在显著的时空相关性,且这一数量在同期有所增加。

结论

本研究结果支持这样一种观点,即奥地利 MG 的患病率正在上升,接近文献中讨论的广泛范围的较高端。我们的数据表明,神经科专家护理对这种疾病的诊断非常重要。

相似文献

1
Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society.奥地利重症肌无力的流行病学:老龄化社会中患病率的上升。
Wien Klin Wochenschr. 2012 Nov;124(21-22):763-8. doi: 10.1007/s00508-012-0258-2. Epub 2012 Nov 6.
2
A population based epidemiological study on myasthenia gravis in Estonia.爱沙尼亚一项基于人群的重症肌无力流行病学研究。
J Neurol Neurosurg Psychiatry. 2003 Dec;74(12):1638-43. doi: 10.1136/jnnp.74.12.1638.
3
Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data.法国重症肌无力的流行病学:基于国家医保报销数据的发病率、患病率和共病情况。
Rev Neurol (Paris). 2024 May;180(5):451-458. doi: 10.1016/j.neurol.2024.02.392. Epub 2024 Apr 5.
4
Epidemiology of myasthenia gravis in Ontario, Canada.加拿大安大略省重症肌无力的流行病学
Neuromuscul Disord. 2016 Jan;26(1):41-6. doi: 10.1016/j.nmd.2015.10.009. Epub 2015 Oct 27.
5
A national epidemiological study of Myasthenia Gravis in Australia.澳大利亚重症肌无力的全国性流行病学研究。
Eur J Neurol. 2012 Nov;19(11):1413-20. doi: 10.1111/j.1468-1331.2012.03698.x. Epub 2012 Apr 2.
6
Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.葡萄牙北部重症肌无力的流行病学:病例的频率估计及临床流行病学分布
Muscle Nerve. 2016 Sep;54(3):413-21. doi: 10.1002/mus.25068. Epub 2016 Jul 4.
7
Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data.2000 年至 2019 年期间英国神经肌肉疾病的患病率和发病率:一项使用初级保健数据的回顾性研究。
PLoS One. 2021 Dec 31;16(12):e0261983. doi: 10.1371/journal.pone.0261983. eCollection 2021.
8
Nationwide population-based epidemiological study of myasthenia gravis in taiwan.台湾重症肌无力的全国基于人群的流行病学研究。
Neuroepidemiology. 2010;35(1):66-71. doi: 10.1159/000311012. Epub 2010 Jun 3.
9
The Epidemiology of Myasthenia Gravis in Korea.韩国重症肌无力的流行病学
Yonsei Med J. 2016 Mar;57(2):419-25. doi: 10.3349/ymj.2016.57.2.419.
10
Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China.中国南方和北方医院和医疗保健保险系统基于记录的重症肌无力流行病学研究。
Neurol Sci. 2020 May;41(5):1211-1223. doi: 10.1007/s10072-019-04146-1. Epub 2020 Jan 3.

引用本文的文献

1
A nationwide epidemiological study of myasthenia gravis in Turkey.土耳其重症肌无力的全国性流行病学研究。
J Neurol. 2024 Dec 12;272(1):5. doi: 10.1007/s00415-024-12781-8.
2
Descriptive analysis of therapeutic outcomes between thoracoscopic and transsternal thymectomy in myasthenia gravis patients from 2011 to 2021.2011 年至 2021 年胸腹腔镜与胸骨正中劈开胸腺切除术治疗重症肌无力患者的疗效描述性分析。
J Cardiothorac Surg. 2024 Sep 3;19(1):510. doi: 10.1186/s13019-024-02983-6.
3
Effect of Thymectomy on Outcomes of Myasthenia Gravis Patients: A Case-Control Study at a Tertiary Care Hospital.

本文引用的文献

1
Myasthenia gravis: a changing pattern of incidence.重症肌无力:发病率的变化模式。
J Neurol. 2010 Dec;257(12):2015-9. doi: 10.1007/s00415-010-5651-z. Epub 2010 Jul 11.
2
A systematic review of population based epidemiological studies in Myasthenia Gravis.一项基于人群的重症肌无力流行病学研究的系统综述。
BMC Neurol. 2010 Jun 18;10:46. doi: 10.1186/1471-2377-10-46.
3
The incidence of myasthenia gravis: a systematic literature review.重症肌无力发病率:系统文献回顾。
胸腺切除术对重症肌无力患者预后的影响:一家三级护理医院的病例对照研究
Cureus. 2023 Apr 14;15(4):e37584. doi: 10.7759/cureus.37584. eCollection 2023 Apr.
4
Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018.2018 年日本重症肌无力的两步全国性流行病学调查。
PLoS One. 2022 Sep 21;17(9):e0274161. doi: 10.1371/journal.pone.0274161. eCollection 2022.
5
Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis.胸腺瘤切除术后重症肌无力患者的短期和持续临床反应。
Eur J Neurol. 2022 Aug;29(8):2453-2462. doi: 10.1111/ene.15362. Epub 2022 Apr 30.
6
Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data.2000 年至 2019 年期间英国神经肌肉疾病的患病率和发病率:一项使用初级保健数据的回顾性研究。
PLoS One. 2021 Dec 31;16(12):e0261983. doi: 10.1371/journal.pone.0261983. eCollection 2021.
7
Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.全球重症肌无力的患病率及常用药物治疗效果的系统评价和荟萃分析。
J Transl Med. 2021 Dec 20;19(1):516. doi: 10.1186/s12967-021-03185-7.
8
Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.依库珠单抗在日本全身性重症肌无力患者中的安全性和有效性:上市后监测的中期分析
Ther Adv Neurol Disord. 2021 Mar 16;14:17562864211001995. doi: 10.1177/17562864211001995. eCollection 2021.
9
The epidemiology of myasthenia gravis.重症肌无力的流行病学。
J Med Life. 2021 Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145.
10
Frequency and clinical features of treatment-refractory myasthenia gravis.治疗抵抗性重症肌无力的频率和临床特征。
J Neurol. 2020 Apr;267(4):1004-1011. doi: 10.1007/s00415-019-09667-5. Epub 2019 Dec 11.
Neuroepidemiology. 2010;34(3):171-83. doi: 10.1159/000279334. Epub 2010 Feb 2.
4
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.美国医院中重症肌无力及重症肌无力危象的发病率和死亡率
Neurology. 2009 May 5;72(18):1548-54. doi: 10.1212/WNL.0b013e3181a41211.
5
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.自身免疫性重症肌无力:新出现的临床和生物学异质性
Lancet Neurol. 2009 May;8(5):475-90. doi: 10.1016/S1474-4422(09)70063-8.
6
Racial differences in myasthenia gravis in Alabama.阿拉巴马州重症肌无力的种族差异。
Muscle Nerve. 2009 Mar;39(3):328-32. doi: 10.1002/mus.21191.
7
Myasthenia gravis in the elderly: Is it different?老年重症肌无力:它有所不同吗?
Ann N Y Acad Sci. 2008;1132:238-43. doi: 10.1196/annals.1405.040.
8
Incidence of seropositive myasthenia gravis in Cape Town and South Africa.开普敦及南非血清阳性重症肌无力的发病率。
S Afr Med J. 2007 Oct;97(10):959-62.
9
Myasthenia gravis: past, present, and future.重症肌无力:过去、现在与未来。
J Clin Invest. 2006 Nov;116(11):2843-54. doi: 10.1172/JCI29894.
10
Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis.迟发性抗乙酰胆碱受体抗体血清阳性重症肌无力的发病率不断上升。
Neurology. 2005 Sep 27;65(6):928-30. doi: 10.1212/01.wnl.0000176067.32186.a3.